Huaren Pharmaceutical Co., Ltd.

Equities

300110

CNE100000SW1

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
3.7 CNY +2.49% Intraday chart for Huaren Pharmaceutical Co., Ltd. +10.45% -12.32%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Huaren Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Huaren Pharma's Unit Gets Nod for Medical Device MT
Huaren Pharma's Unit Gets Nod to Add Specifications to Antibiotic Product MT
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Huaren Pharmaceutical Co., Ltd.(XSEC:300110) added to S&P Global BMI Index CI
Huaren Pharmaceutical Co., Ltd. Announces Director Appointments CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Huaren Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 12 July 2023 CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Huaren Pharmaceutical Co., Ltd. Proposes Final Dividend for 2022 CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Huaren Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.339851 billion in funding from Xi'an Qujiang Tianshou Great Health Investment Partnership Enterprise ( Limited Partnership) CI
Huaren Pharma Appoints Executive President MT
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Huaren Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 17, 2022 CI
Huaren Pharmaceutical Co., Ltd. Approves Board Appointments CI
Huaren Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2021 CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Huaren Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021 CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Huaren Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Chart Huaren Pharmaceutical Co., Ltd.
More charts
Huaren Pharmaceutical CO.,LTD is a China-based company principally engaged in the research, development, manufacture and distribution of non polyvinyl chloride (PVC) soft bag large volume preparations. The Company provides basic infusion products, including sodium chloride infusions, dextrose infusions and compound sodium chloride infusions, among others; infusion products for treatment, including metronidazole and sodium chloride infusions, ciprofloxacin lactate and sodium chloride infusions and others, as well as nutritious infusion products, among others. The Company distributes its products in domestic market, with Northeast China as its main market.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 300110 Stock
  4. News Huaren Pharmaceutical Co., Ltd.
  5. Huaren Pharma's Unit Gets Nod for Medical Device